Abstract: The present invention generally relates to methods and compositions for generating vancomycin analogs. Specifically the invention relates to generating a vancomycin library through chemoselective ligation of a sugar moiety with a vancomycin aglycon. In particular, the present invention provides a library of vancomycin analogs, where the member of the library comprises at least one vancomycin analog selected from 2?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 3?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 4?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 6?-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 2?-N-acylbiphenyl-glucosyl vancomycin neoglycoside, 3?-N-acylbiphenoyl-glucosyl vancomycin neoglycoside, 4?-N-acylbiphenoyl-glucosyl vancomycin neoglycoside and 6?-N-acylbiphenoyl-glucosyl vancomycin neoglycoside.
Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
Type:
Grant
Filed:
April 26, 2010
Date of Patent:
April 29, 2014
Assignee:
Cardiopep Pharma GmbH
Inventors:
Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
Abstract: Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.
Type:
Grant
Filed:
June 23, 2009
Date of Patent:
April 22, 2014
Assignee:
ELC Management, LLC
Inventors:
Daniel H. Maes, Nadine A. Pernodet, Thomas Mammone, Edward Pelle, Donald F. Collins, Lenny Slutsky, Kerri Goldgraben
Abstract: A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes.
Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
Type:
Grant
Filed:
December 18, 2009
Date of Patent:
April 15, 2014
Assignee:
Indiana University Research and Technology Corporation
Inventors:
Richard D. DiMarchi, Binbin Kou, Shujiang Cheng
Abstract: The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by suppressing the transfer of PI3K signals, the fifth zinc finger domain of FOG2 according to the present invention can be suitably use as a composition for the prevention and treatment of PI3K-related diseases.
Type:
Grant
Filed:
June 8, 2010
Date of Patent:
March 18, 2014
Assignee:
Seoul National University R&DB Foundation
Abstract: The present invention relates to a coacervate comprising a mussel adhesive protein and an anionic polymer, and more particularly, to a coacervate prepared by mixing a mussel adhesive protein with an anionic polymer, and a novel use thereof. In the present invention, a coacervate prepared by mixing a mussel adhesive protein and an anionic polymer shows a very excellent adhesive strength to various substrates such as cells or metals, and is able to maintain its adhesive strength in the presence of water or under water, thereby being effectively used as an adhesive. Moreover, it has an activity capable of encapsulating bioactive materials, thereby being effectively used as an active component of a composition for delivering bioactive materials.
Abstract: The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
March 4, 2014
Assignee:
The Regents of the University of Michigan
Inventors:
Yuqing E. Chen, Changyong Xue, Jifeng Zhang
Abstract: The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of determining the affinity of a test compound for a ribosomal subunit.
Type:
Grant
Filed:
August 18, 2008
Date of Patent:
February 11, 2014
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Beatriz Llano-Sotelo, Alexander S. Mankin, Dorota Klepacki
Abstract: The invention relates to a composition containing an extract of seeds of Acacia macrostachya. Advantageously the composition is cosmetic, pharmaceutical, dermatological or nutraceutical. The invention also relates to a method for extracting a Acacia macrostachya seed extract, as well as to the resulting extract. The invention further relates to one such composition or one such extract for use in the prevention or treatment of disorders and diseases affecting the skin, mucosae or appendages, for use in the prevention or treatment of vascular disorders and for use in the prevention or treatment of adipose tissue alterations. Moreover, the invention relates to a method for cosmetic care of the Skin, appendages and mucosae in order to improve the condition or appearance thereof, comprising the administration of one such composition or one such extract.
Type:
Grant
Filed:
November 30, 2010
Date of Patent:
February 4, 2014
Assignee:
Laboratoires Expanscience
Inventors:
Philippe Msika, Alex Saunois, Sophie Leclere-Bienfait, Caroline Baudoin
Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.
Type:
Grant
Filed:
March 28, 2013
Date of Patent:
January 28, 2014
Assignees:
St George's Hospital Medical School, The University of Manchester
Inventors:
Clive Robinson, Jihui Zhang, David Ronald Garrod, Trevor Robert Perrior, Gary Karl Newton, Kerry Jenkins, Rebekah Elisabeth Key, Meriel Ruth Major, Mark Richard Stewart
Abstract: The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.
Type:
Grant
Filed:
July 11, 2008
Date of Patent:
January 28, 2014
Assignees:
University of Washington Through Its Center for Commercialization, Florida Gulf Coast University
Inventors:
Scott F. Michael, Sharon Isern, Joshua Costin, Vaikuntanath Samudrala, Ekachai Jenwitheesuk
Abstract: Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine.
Abstract: The present disclosures provides isolated or purified compounds, each of which bind to a metal atom. Generally, the compounds are small in size (e.g, molecular weight of less than about 1 kDa) and peptidic in nature, inasmuch as the compounds comprise amino acids. In some embodiments, the compound comprises a structure of Formula I: M1-P1-M2-P2 wherein each of P1 and P2 is a peptide comprising at least two amino acids, M1 is a first metal binding moiety comprising a substituted imidazolone ring, M2 is a second metal binding moiety comprising a substituted oxazolone ring, and wherein M1 and M2 bind to a single metal atom. Also provided are related complexes, conjugates, cells which synthesize the compounds of the present disclosures, substantially homogenous cultures thereof, kits and compositions, and methods of making or using the materials of the present disclosures.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
January 14, 2014
Assignees:
Iowa State University Research Foundation, Inc., The Regents of the University of Michigan, WiSys Technology Foundation
Inventors:
Jeremy D. Semrau, Warren Gallagher, Sukhwan Yoon, Jeongdae Im, Alan A. DiSpirito, Sung-Woo Lee, Scott Hartsel, Marcus T. McEllistrem
Abstract: Specific template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilization of stem cells.
Type:
Grant
Filed:
February 5, 2010
Date of Patent:
January 14, 2014
Inventors:
Frank Otto Gombert, Alexander Lederer, Daniel Obrecht, Barbara Romagnoli, Christian Bisang, Christian Ludin
Abstract: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.
Type:
Grant
Filed:
April 15, 2010
Date of Patent:
January 14, 2014
Assignee:
National Research Council of Canada
Inventors:
Rana Filfil, Dmitri Tolkatchev, Feng Ni, Maureen D. O'Connor-McCourt, Anne E. G. Lenferink
Abstract: The present invention relates to phosphopeptide compositions and anti-phosphopeptide antibody compositions. Also provided are methods of identifying phosphorylation sites in phosphorylated peptides and phosphorylation site motifs.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
December 31, 2013
Assignee:
President and Fellows of Harvard College
Inventors:
Steven P. Gygi, Judit Villen, Sean Beausoleil
Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
Type:
Grant
Filed:
December 21, 2011
Date of Patent:
December 31, 2013
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
Abstract: The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcR? signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents).